MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Rilzabrutinib

CAS No. : 1575596-29-0

MCE 站：Rilzabrutinib

产品活性：Rilzabrutinib (PRN1008) 是布鲁顿氏酪氨酸激酶 (BTK) 可逆的、选择性的、有口服活性的共价抑制剂，其 IC₅₀ 值为 1.3 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：Btk

In Vitro: Rilzabrutinib is a reversible covalent inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC₅₀ of 1.3±0.5 nM. Rilzabrutinib is also found to be highly selectively when tested in a panel of 251 other kinases. Cysteine targeting of BTK by Rilzabrutinib results in a slow off-rate demonstrated by retention of 79±2% of binding to BTK in PBMC 18 hours after washing away the compound in vitro. The covalent cysteine binding is completely reversible after denaturation of the target. Anti-IgM induces human B cell proliferation (10% serum) and B cell CD69 expression are inhibited by Rilzabrutinib with IC₅₀ of 5±2.4 nM and 123±38 nM, respectively.

In Vivo: In vivo Rilzabrutinib demonstrates enduring pharmacodynamic effects after the compound has cleared from circulation, consistent with extended target residence time. Rilzabrutinib also reverses and completely suppresses collagen-induced arthritis in rats in a dose dependent manner which allows correlation of target occupancy and disease modification.

相关产品：Covalent Screening Library Plus  |  Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Covalent Screening Library  |  Orally Active Compound Library  |  Anti-Blood Cancer Compound Library  |  Ibrutinib  |  Acalabrutinib  |  Zanubrutinib  |  Fenebrutinib  |  ARQ 531  |  Pirtobrutinib  |  Orelabrutinib  |  Tirabrutinib  |  Spebrutinib  |  BMX-IN-1  |  Ibrutinib-biotin  |  Vecabrutinib  |  Tolebrutinib  |  MT-802  |  CGI-1746  |  Remibrutinib  |  SJF620  |  Ibrutinib deacryloylpiperidine  |  QL47  |  PCI-33380  |  BIIB068  |  GDC-0834  |  LFM-A13  |  Poseltinib  |  Branebrutinib  |  CNX-500  |  PCI 29732

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  染料试剂  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。